4BIO Capital co-leads Actithera’s oversubscribed $75.5 million Series A financing

Contributed by: GlobeNewswire

Tags

Healthcare

More Like This

PR Newswire associated0

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

EQT Life Sciences leads EUR 93 million oversubscribed Series A round in PanTera, which aims to accelerate global actinium - 225 production

PR Newswire associated0

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors

PR Newswire associated0

Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies

4BIO Capital Strengthens Investment Team

EQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's disease

PR Newswire associated0

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics